Bone Biologics is developing a targeted approach to bone regeneration through its proprietary NELL-1 platform, designed to address the li...
Q2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the...
Merck has reported strong financial results for the second quarter of 2026, driven by sustained growth across its Life Science and Electronics businesses...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced financial results...
Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Dilut...
Pharmaceutical marketing is undergoing a significant transformation as companies balance regulatory complexity, digital disruption, evolving workforce ex...
In biopharma, critical decisions are often shaped by more than clinical data, regulatory insights, or operational metrics. The most important signals m...
Artificial intelligence is transforming the role of advanced practice providers (APPs) by streamlining documentation, simplifying clinical workfl...
In the Annex 1 era, media fills must replicate the routine aseptic manufacturing process as closely as possible. This includes all critical manufacturing s...
Targeted genetic medicines are reshaping the future of cancer treatment by improving the precision of therapeutic delivery while addressing the challenges ...
Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09 Pharma launches sales increased by 48.3%, reaching €1.3 bil...
“We delivered outstanding performance in the second quarter, reflecting the strength of our proven growth strategy, our team’s excellen...
Danaher Corporation announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-per...
In H1 2026, Lonza1 delivered sales of CHF 3.4 billion with +16.0% CER2 sales growth The CORE EBITDA margin significantly expanded by +4.4...
© 2026 Biopharma Boardroom. All Rights Reserved.
